Medtronic reported plans to partitioned its diabetes division, which includes insulin pumps and wearable devices, into an autonomous company. In spite of later battles due to administrative concerns over quality administration and cybersecurity, the unit has returned to development.
The company too forecasted its adjusted 2026 benefit below market expectations.
Related News